ECCO 2022


Ulcerative colitis clinical trials on treatment effects: a comparison of clinical, endoscopic and histological remission (ECCO 2022)

15/03 - Clinical remission, defined by the Mayo Clinic Score (MCS) or modified MCS, is the accepted regulatory endpoint in drug development for ulcerative colitis (UC). Whilst histologic remission is a more stringent outcome, recent trials have reported numerically higher rates compared to endoscopic or clinical remission rates at the same timepoint, suggesting that histologic remission may be ...

Schrijf u gratis in

Om toegang te krijgen tot nationale en internationale medische informatie op al uw schermen.

Vaccination against SARS-COV-2 infection in IBD patients: should we prioritize an additional booster injection? (ECCO...

On the way to Crohn's disease and ulcerative colitis control: fatigue as part of a novel composite endpoint (ECCO 2022)

Insights from patients with Ulcerative Colitis on disease burden Findings from a real-world survey in Europe (ECCO 2022)

'Superdonor' Samples Don't Increase FMT Success in Ulcerative Colitis (ECCO 2022)

Two Factors Linked to Higher Risk of Long COVID in IBD (ECCO 2022)

Om veiligheidsredenen is uw browser niet compatibel met onze site

We raden u aan een van de volgende browsers te gebruiken: